Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GLP-1 High Dose Clear all
Not yet recruiting Phase 4 Interventional

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

NCT07832084
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

NCT07693608
View directory record Official record
Conditions
Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
Interventions
Tirzepatide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

NCT07212868
View directory record Official record
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
View directory record Official record
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Concord, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413
View directory record Official record
Conditions
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions
RO7204239, RO7204239 Matching Placebo, Tirzepatide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

NCT01381926
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Bone Remodeling
Interventions
exenatide, Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
45 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

NCT06003153
View directory record Official record
Conditions
Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Interventions
oral semaglutide, Mixed Meal Tolerance Test (MMTT)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Glycogen and Hypoglycemia in Humans

NCT03241706
View directory record Official record
Conditions
Hypoglycemia; Iatrogenic
Interventions
Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
Drug
Lead sponsor
Jason Winnick
Other
Eligibility
21 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Liraglutide, Insulin
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Not yet recruiting Not applicable Interventional

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

NCT07796204
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Almond Diet
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

NCT03235050
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Slowly Digestible Carbohydrates for GLP-1 Secretion

NCT07572513
View directory record Official record
Conditions
Blood Glucose, GLP-1, Satiety, Second Meal Intake, Healthy Participant Study
Interventions
Maltodextrin (Placebo), Raw Corn Starch
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Results available

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

NCT04779697
View directory record Official record
Conditions
Obesity
Interventions
GLP-1 analogue - semaglutide, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

NCT03057509
View directory record Official record
Conditions
Small Bowel Carcinoid Tumor
Interventions
Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software, LAR Octreotide
Drug · Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Action in Physiology and Diabetes

NCT02550548
View directory record Official record
Conditions
Insulin Secretion
Interventions
GIP infusion, GLP-1 infusion, Ex-9 infusion
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Effect of Supplement on Appetite and GLP-1

NCT06790771
View directory record Official record
Conditions
Hunger
Interventions
High Dose Supplement, Low Dose Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Liraglutide, Saline
Drug
Lead sponsor
Ildiko Lingvay
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Fibrosis Lessens After Metabolic Surgery

NCT06374875
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions
Metabolic surgery, Incretin-Based Therapy
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 4:09 PM EDT